November 21, 2024
With many new agents under development, including immuno- and targeted therapies, predictive research models such as patient-derived xenografts (PDX) are required for preclinical evaluation. PDX models are proven to be highly predictive models for preclinical drug assessment. The Crown Bioscience bladder cancer PDX collection consists of a wide range of models, including subcutaneous and orthotopic models to more closely recapitulate the tumor microenvironment and models carrying FGFR3 and TSC1 mutations. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER | CANCER TYPE | CANCER SUBTYPE | DESCRIPTION | # per page |
---|---|---|---|---|
BL0597 | Bladder Cancer | SCC | Poorly to moderately differentiated squamous cell carcinoma | CLICK TO VIEW |
BL2350 | Bladder Cancer | ADC | Urachal adenocarcinoma | CLICK TO VIEW |
BL2393 | Bladder Cancer | Sarcoma | Spindel cell tumor of bladder. Consider liomyosarcoma on basis of IHC results. The tumor is lined in bundles, mitotic figure: 13-17/10 HPF, infiltrated through bladder wall. | CLICK TO VIEW |
BL3249 | Bladder Cancer | SCC | Bladder: infiltrative urothelial carcinoma with squamous differentiation and adenoid differentiation, tumor invasive to adventitia of bladder and form cancer node. | CLICK TO VIEW |
BL3325 | Bladder Cancer | ADC | Bladder: infiltrative urothelial carcinoma, low grade. One of fourteen lymph nodes involved by metastatic carcinoma (1/14). | CLICK TO VIEW |
BL3338 | Bladder Cancer | ADC | Adenocarcinoma | CLICK TO VIEW |
BL3479 | Bladder Cancer | NA | Bladder: infiltrating urothelial carcinoma, high grade, infiltrating through bladder wall | CLICK TO VIEW |
BL3578 | Bladder Cancer | NA | Bladder: infiltrating urothelial carcinoma, infiltrating through bladder wall | CLICK TO VIEW |
BL5001 | Bladder Cancer | TCC | bladder carcinoma, transitional cell carcinoma, pd. Pathol comment: c/w diagnosis. approximately 80% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
BL5003 | Bladder Cancer | TCC | bladder carcinoma, transitional cell carcinoma. Pathol comment: c/w diagnosis. approximately 80% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
BL5006 | Bladder Cancer | TCC | bladder carcinoma, metastatic transitional cell bladder cancer. Pathol comment: c/w diagnosis. approximately 80% of the tissue involved by malignant tumor in sections examined. malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
BL5007 | Bladder Cancer | TCC | bladder carcinoma, transitional cell carcinoma. Pathol comment: c/w diagnosis. approximately 10% of the tissue involved by malignant tumor in sections examined. focal tumor necrosis. malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
BL5368 | Bladder Cancer | NA | Bladder Cancer. Pathol comment: c/w diagnosis. Microscopic focus of malignant tumor present in tissue sections examined. Malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
BL5384 | Bladder Cancer | NA | Bladder Carcinoma. Pathol comment: c/w diagnosis. Approximately 50% of the tissue involved by maligmant tumor in sections examined. 10% necrotic. Malignant tumor cells in cytospin prep. | CLICK TO VIEW |
BL5420 | Bladder Cancer | NA | Oat cell | CLICK TO VIEW |
BL5422 | Bladder Cancer | NA | Bladder Carcinoma. Pathol comment: Tumor cells present in cell block and cytospin prep. | CLICK TO VIEW |
BL5425 | Bladder Cancer | NA | Bladder carcinoma. Pathol comment: Approximately 70% of the tissue involved by maligmant tumor in sections examined. Malignant tumor cells present in cytospin prep. | CLICK TO VIEW |
BL5428 | Bladder Cancer | NA | Bladder Carcinoma. C/W DIAGNOSIS. APPROXIMATELY 50% OF THE TISSUE INVOLVED BY MALIGNANT TUMOR IN SECTIONS EXAMINED. MALIGNANT TUMOR CELLS PRESENT IN CYTOSPIN PREP. | CLICK TO VIEW |
BL9200 | Bladder Cancer | NA | NA | CLICK TO VIEW |
BL9201 | Bladder Cancer | N/A | N/A | CLICK TO VIEW |
BL9208 | Bladder Cancer | NA | NA | CLICK TO VIEW |
BL9210 | Bladder Cancer | NA | NA | CLICK TO VIEW |
BL9211 | Bladder Cancer | N/A | N/A | CLICK TO VIEW |
BL9212 | Bladder Cancer | NA | NA | CLICK TO VIEW |
BL9213 | Bladder Cancer | NA | NA | CLICK TO VIEW |
BL9214 | Bladder Cancer | NA | NA | CLICK TO VIEW |
BL9216 | Bladder Cancer | N/A | N/A | CLICK TO VIEW |
BL9217 | Bladder Cancer | N/A | N/A | CLICK TO VIEW |
Already Registered? Login
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy